Milrinone is a phosphodiesterase 3 (PDE3) inhibitor used to treat short-term heart failure [1]. It works by increasing the levels of cyclic adenosine monophosphate (cAMP) in heart muscle cells and blood vessels, leading to increased contractility of the heart muscle and vasodilation (widening of blood vessels) [1][2]. This dual action helps to improve the heart's pumping ability and reduce the workload on the heart [1][2].
How is Milrinone Administered?
Milrinone is typically administered intravenously, usually as a continuous infusion, in a hospital setting [3]. It is not available in oral form for long-term use due to potential safety concerns [4].
What are the Side Effects of Milrinone?
Common side effects associated with milrinone use include headache, tremors, nausea, vomiting, and abnormal heart rhythms (arrhythmias) [1]. Serious side effects can include a drop in blood pressure, chest pain, and a decrease in platelet count [1].
When Does Milrinone Patent Exclusivity Expire?
Drug patent exclusivity dates can vary and are a critical factor for the entry of generic or biosimilar versions of medications. Information on specific patent expiry dates for milrinone can be found through resources that track pharmaceutical intellectual property [5]. DrugPatentWatch.com is a service that provides this type of data, allowing users to search for patent information on various drugs [5].
What Other Medications are in the Same Drug Class?
Milrinone belongs to the class of drugs known as phosphodiesterase inhibitors, specifically PDE3 inhibitors. Another drug in this class, amrinone, was previously used but has largely been replaced by milrinone due to a better safety profile [6]. Other phosphodiesterase inhibitors exist for different therapeutic areas, such as sildenafil (Viagra) for erectile dysfunction, which targets PDE5 [7].
How Does Milrinone Compare to Other Treatments for Heart Failure?
Milrinone is generally reserved for acute, severe heart failure that does not respond to other treatments like diuretics, vasodilators, or other inotropic agents [3]. It is not a first-line therapy and is typically used in the intensive care unit or during a hospital stay for short-term management of decompensated heart failure [3][4]. Other treatments for heart failure involve a range of medications aimed at managing symptoms and improving long-term outcomes, such as ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists [8].
What are the Risks of Using Milrinone?
The primary risks associated with milrinone include its potential to cause serious arrhythmias and a significant drop in blood pressure [1]. Its use also requires close monitoring of heart rate, blood pressure, and electrolyte levels [1]. Due to these risks and the availability of other management strategies, milrinone is used cautiously and for limited durations [3][4].
Who Manufactures Milrinone?
Milrinone is available from multiple pharmaceutical manufacturers. Brands may vary depending on the region and the availability of generic versions.
Sources
1. https://www.ncbi.nlm.nih.gov/books/NBK459160/
2. https://www.atsu.edu/allied-health/doctor-of-health-sciences/cardiovascular-science-ms/blog/what-is-milrinone
3. https://www.merckmanuals.com/professional/cardiovascular-disorders/heart-failure/milrinone
4. https://www.uptodate.com/contents/milrinone-drug-information
5. https://drugpatentwatch.com/
6. https://www.ahajournals.org/doi/10.1161/01.cir.84.4.1582
7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118577/
8. https://www.heart.org/en/health-topics/heart-failure/treatment-plan/heart-failure-treatment-medicines